New life for EGFR at ASCO21

This year’s ASCO features a series of compounds and combos taking aim at resistance mechanisms plaguing the sea of marketed therapies against EGFR.

The biggest focus is on EGFR-mutant non-small cell lung cancer (NSCLC), an indication where resistance to EGFR-targeting tyrosine kinase inhibitors (TKIs) frequently emerges, and where patients with certain mutations have historically been left behind...